Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Alerts
  • Advertising
  • Job board
  • Subscribe
  • Contact
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Author's Takes
  • Reviews
    • View all reviews ...
    • Aging (Upcoming)
    • Next-Generation Sequencing in Medicine (Jun 2022)
    • New Therapeutic Targets in Cardiovascular Diseases (Mar 2022)
    • Immunometabolism (Jan 2022)
    • Circadian Rhythm (Oct 2021)
    • Gut-Brain Axis (Jul 2021)
    • Tumor Microenvironment (Mar 2021)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Commentaries
    • Concise Communication
    • Editorials
    • Viewpoint
    • Top read articles
  • Clinical Medicine
  • JCI This Month
    • Current issue
    • Past issues

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Author's Takes
  • In-Press Preview
  • Commentaries
  • Concise Communication
  • Editorials
  • Viewpoint
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Alerts
  • Advertising
  • Job board
  • Subscribe
  • Contact
E2f8 mediates tumor suppression in postnatal liver development
Lindsey N. Kent, … , Alain de Bruin, Gustavo Leone
Lindsey N. Kent, … , Alain de Bruin, Gustavo Leone
Published July 25, 2016
Citation Information: J Clin Invest. 2016;126(8):2955-2969. https://doi.org/10.1172/JCI85506.
View: Text | PDF
Research Article Oncology

E2f8 mediates tumor suppression in postnatal liver development

  • Text
  • PDF
Abstract

E2F-mediated transcriptional repression of cell cycle–dependent gene expression is critical for the control of cellular proliferation, survival, and development. E2F signaling also interacts with transcriptional programs that are downstream of genetic predictors for cancer development, including hepatocellular carcinoma (HCC). Here, we evaluated the function of the atypical repressor genes E2f7 and E2f8 in adult liver physiology. Using several loss-of-function alleles in mice, we determined that combined deletion of E2f7 and E2f8 in hepatocytes leads to HCC. Temporal-specific ablation strategies revealed that E2f8’s tumor suppressor role is critical during the first 2 weeks of life, which correspond to a highly proliferative stage of postnatal liver development. Disruption of E2F8’s DNA binding activity phenocopied the effects of an E2f8 null allele and led to HCC. Finally, a profile of chromatin occupancy and gene expression in young and tumor-bearing mice identified a set of shared targets for E2F7 and E2F8 whose increased expression during early postnatal liver development is associated with HCC progression in mice. Increased expression of E2F8-specific target genes was also observed in human liver biopsies from HCC patients compared to healthy patients. In summary, these studies suggest that E2F8-mediated transcriptional repression is a critical tumor suppressor mechanism during postnatal liver development.

Authors

Lindsey N. Kent, Jessica B. Rakijas, Shusil K. Pandit, Bart Westendorp, Hui-Zi Chen, Justin T. Huntington, Xing Tang, Sooin Bae, Arunima Srivastava, Shantibhusan Senapati, Christopher Koivisto, Chelsea K. Martin, Maria C. Cuitino, Miguel Perez, Julian M. Clouse, Veda Chokshi, Neelam Shinde, Raleigh Kladney, Daokun Sun, Antonio Perez-Castro, Ramadhan B. Matondo, Sathidpak Nantasanti, Michal Mokry, Kun Huang, Raghu Machiraju, Soledad Fernandez, Thomas J. Rosol, Vincenzo Coppola, Kamal S. Pohar, James M. Pipas, Carl R. Schmidt, Alain de Bruin, Gustavo Leone

×

Figure 1

Loss of atypical E2Fs leads to carcinogen-induced HCC.

Options: View larger image (or click on image) Download as PowerPoint
Loss of atypical E2Fs leads to carcinogen-induced HCC.
(A) Box plots sho...
(A) Box plots showing the mRNA levels of E2F7 and E2F8 from patients with normal or diseased livers derived from Affymterix Microarrays, Wilcoxon tests with Bonferroni’s correction for multiple tests. *, vs. control: E2F7 HCC-early, P = 0.020; HCC-advanced, P < 0.001; E2F8 HCC-early, P = 0.001; and HCC-advanced, P < 0.001. (B) Promoter occupancy of E2Fs on the E2f8 promoter. E2F1, E2F3A, and E2F3B tags were identified by ChIP-seq conducted in MEFs overexpressing E2F1, E2F3A, or E2F3B. (C) Correlation between expression of E2F7/8 and MKI67 mRNA levels in the data set described in A. P values, linear regression analysis. (D) Representative pictures of livers (top) and H&E-stained liver sections (below) from DEN-treated 9-month-old 7fl/fl 8fl/fl (control), Alb-Cre 7fl/fl (7Δ/Δ), Alb-Cre 8fl/fl (8Δ/Δ), and Alb-Cre 7fl/fl 8fl/fl (7Δ/Δ 8Δ/Δ) male mice. Areas of HCC are outlined by dotted lines. T and N, tumor and normal liver, respectively. Scale bars: 1 cm (top) and 100 μm (bottom). (E) Box plots showing the ratio of liver vs. body weight (liver/body wt.) of 9-month-old DEN-treated male mice. Outliers are represented by gray dots. Wilcoxon tests with Bonferroni’s correction. *, vs. control: 7Δ/Δ, P = 0.009; 8Δ/Δ, P < 0.001; and 7Δ/Δ 8Δ/Δ, P < 0.001. (F) Histopathological analysis of livers from E. FCA, focal cellular atypia, NSL, no significant lesions. Fisher’s exact tests with Bonferroni’s correction. *, carcinoma (focal/multifocal) vs. control: 7Δ/Δ, P = 0.004; and 8Δ/Δ, P = 0.13. ‡, multifocal carcinoma vs. control: 8Δ/Δ, P < 0.001; and 7Δ/Δ 8Δ/Δ, P = 0.015. (G) Box plots showing liver/body wt. of 9-month-old DEN-treated female mice. Wilcoxon tests with Bonferroni’s correction. *, 7Δ/Δ 8Δ/Δ vs. control, P < 0.001. (H) Histopathological analysis of livers from G. Fisher’s exact tests with Bonferroni’s correction. *P = 0.026, carcinoma vs. control. n, number of mice or patients per group.

Copyright © 2022 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts